FTC’s Ban of Noncompete Agreements Halted
With the rule recently struck down by a Texas court, how should employers, including labs, handle such agreements going forward?
Essential
Subscribe today for access to
Articles and Reports
Six Sigma Can Help Monitor New CLIA Proficiency Testing Changes
A PT update went into effect on January 1, focusing on revised acceptance limits, among other modifications
ProPhase Labs’ Resolution for 2025: Nail Down a ‘Liquidity Event’
The company has lost nearly $36 million since 2023, but its CEO is aggressively pursuing new revenue options
CMS Delays Controversial Hospital Price Transparency Rules
...
Already a member? Log in here
Reimbursement: CMS Increases 2020 AIC Medicare Appeal Thresholds
...
Already a member? Log in here
Quest Shells Out $195K to Settle Massive HIV Data Breach Class Action
...
Already a member? Log in here
Global News: EU Delays Launch of Eudamed Database
...
Already a member? Log in here
PAMA Report: ACLA Tries for Decisive Blow in Federal Court Case
...
Already a member? Log in here
ACLA Goes for Knockout Punch in PAMA Lawsuit
...
Already a member? Log in here
Medicare Reimbursement: CMS Eases Coverage Restrictions on NGS Testing of Early-Stage Cancer Patients
...
Already a member? Log in here
Lab Fails in Bid to Get Medicare Payment Suspension Set Aside
...
Already a member? Log in here
Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month
Although briskness in alliances partially offset sluggishness in M&A, October was far less dynamic than September for strategic deal making within the diagnostics sector. Here’s an overview of the key deals that did come down over the 4-week period beginning in late September 2019.
FDA Watch: New Process for Simultaneous Review IVD Tests Used in Cancer Drug Trials
Typically, in vitro diagnostic (IVDs) tests used in investigational cancer drug trials require two submissions: one for the IVD test and another for the drug. But on Oct. 9, the FDA issued final guidance allowing companies to submit for simultaneous review for the clinical trial.